<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935399</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056660</org_study_id>
    <nct_id>NCT03935399</nct_id>
  </id_info>
  <brief_title>Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin</brief_title>
  <official_title>Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to evaluate the effects that a dose of oxytocin given by intramuscular&#xD;
      (IM) injection (into the muscle) will have on an area of skin that has been exposed to&#xD;
      ultraviolet (UV) light. The area of skin exposed to UV light will have a mild sun burn&#xD;
      feeling.&#xD;
&#xD;
      Sensory testing will be performed on the area of UV burn. The area will be evaluated for&#xD;
      sensitivity in 3 methods: touch, vibratory&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol aims to provide an estimate of effect size of intramuscular oxytocin on a test&#xD;
      of Aβ and of Aδ fiber sensitivity in injured skin following ultraviolet B (UVB) burned skin.&#xD;
&#xD;
      For the primary goal - to examine the effects of oxytocin peripheral nerves after tissue&#xD;
      injury - the investigators chose the controlled ultraviolet sunburn model.&#xD;
&#xD;
      The investigators propose a randomized, blinded, cross over design with treatment with&#xD;
      oxytocin one day and placebo on another. Following baseline measures on each of the two study&#xD;
      days, participants will receive an intramuscular injection of oxytocin (Pitocin®) in its&#xD;
      indicated dose of 10 IU (17 μg) or an equivalent volume of saline.&#xD;
&#xD;
      In order to determine the highest frequency that Aβ nerve fibers can respond to, the&#xD;
      investigators will use a device that produces an oscillatory / vibratory stimulus which can&#xD;
      be used on the hand.&#xD;
&#xD;
      Pain threshold to punctate stimulation within the area of irradiation will be determined&#xD;
      using calibrated von Frey filaments and an up-down sequential method which efficiently&#xD;
      estimates median thresholds.&#xD;
&#xD;
      Thermal heat testing will also be performed by the surface of the skin of the forearm or leg&#xD;
      is heated to 45°C using a computer controlled thermode for a period of 5 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blinded crossover treatment with oxytocin and placebo (saline)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, Investigator and outcomes assessor will be blinded. Research Pharmacist will prepare the study medication administration and hold the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection</measure>
    <time_frame>From 5 minutes to 120 minutes</time_frame>
    <description>Vibration frequency detection threshold in the burned area after IM Oxytocin or placebo injection will be obtained by the subject placing the forearm area that was exposed to the UV burn on the oscillatory device and informing the investigators when the first perception of vibration is felt. A recording of the frequency (1 kilo Hertz to 1 Hertz) will be documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain Threshold (the Point Where Pain is First Perceived) to a Punctate Mechanical Stimulus After IM Injection.</measure>
    <time_frame>From 5 minutes to 120 minutes</time_frame>
    <description>Verbal pain punctate stimulus detection threshold (the point where pain is first perceived) in the burned area after IM Oxytocin or Placebo injection will be obtained by using von Frey filaments (small filaments that are similar to a paint brush bristle). The skin will be touched with the filaments and the participant will state when pain is perceived and the size of the filament will be documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hypersensitivity to Von Frey Filament (225 milliNewton) After IM Injection.</measure>
    <time_frame>From 5 minutes to 65 minutes</time_frame>
    <description>Hypersensitivity in the burned area after IM Oxytocin or placebo injection will be obtained by using a von Frey filament (small filament that is similar to a paint brush bristle). The skin will be touched with the filament and the participant will state when sensitivity is perceived and the area marked and measured in centimeters squared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vibration Frequency Detection of Fixed Frequency (When Vibration is First Felt) After IM Injection</measure>
    <time_frame>From 5 minutes to 65 minutes</time_frame>
    <description>Vibration frequency detection of a fixed frequency (256 Hertz) in the burned area after IM Oxytocin or placebo injection will be obtained. The subject will place the wrist area that was exposed to the UV burn on the oscillatory device, the fixed vibratory frequency will begin and will be increased in intensity and the subject will inform the investigators when the first perception of vibration is felt. A recording of the intensity level will be documented in Hertz.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sustained Heat After IM Injection Non Dominant Arm</measure>
    <time_frame>From 21 minutes to 125 minutes</time_frame>
    <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature after IM Oxytocin or placebo injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sustained Heat After IM Injection</measure>
    <time_frame>From 36 minutes to 40 minutes</time_frame>
    <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 40 degree Celsius temperature applied to the site of the UV burn after IM Oxytocin or placebo injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sustained Heat After IM Oxytocin or Placebo Injection (Lower Leg)</measure>
    <time_frame>From 21 minutes to 65 minutes</time_frame>
    <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature applied to the calf (lower leg) after IM Oxytocin or placebo injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Oxytocin first, then saline placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo first, then oxytocin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>10 IU oxytocin (Pitocin) for intramuscular injection</description>
    <arm_group_label>Oxytocin first, then saline placebo</arm_group_label>
    <arm_group_label>Saline placebo first, then oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1.5 ml preservative free saline for intramuscular injection</description>
    <arm_group_label>Oxytocin first, then saline placebo</arm_group_label>
    <arm_group_label>Saline placebo first, then oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female &gt; 18 and &lt; 60 years of age,&#xD;
&#xD;
          -  Body Mass Index (BMI) &lt;40&#xD;
&#xD;
          -  Generally in good health as determined by the Principal Investigator based on prior&#xD;
             medical history&#xD;
&#xD;
          -  Normal blood pressure and resting heart rate without medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®&#xD;
&#xD;
          -  Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the&#xD;
             Principal Investigator, would place the subject at increased risk&#xD;
&#xD;
          -  Women who are pregnant (positive result for serum pregnancy test at screening visit),&#xD;
             women who are currently nursing or lactating, women that have been pregnant within 2&#xD;
             years.&#xD;
&#xD;
          -  Neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain&#xD;
             medications on a daily basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03935399/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03935399/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin First, Then Saline Placebo</title>
          <description>Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day&#xD;
Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection&#xD;
Saline: 1.5 ml preservative free saline for intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo First, Then Oxytocin</title>
          <description>Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day&#xD;
Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection&#xD;
Saline: 1.5 ml preservative free saline for intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Study Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Study Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin First, Then Saline Placebo</title>
          <description>Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day&#xD;
Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection&#xD;
Saline: 1.5 ml preservative free saline for intramuscular injection</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo First, Then Oxytocin</title>
          <description>Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day&#xD;
Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection&#xD;
Saline: 1.5 ml preservative free saline for intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="12"/>
                    <measurement group_id="B2" value="40" spread="12"/>
                    <measurement group_id="B3" value="38" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="5"/>
                    <measurement group_id="B2" value="26" spread="3"/>
                    <measurement group_id="B3" value="27" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection</title>
        <description>Vibration frequency detection threshold in the burned area after IM Oxytocin or placebo injection will be obtained by the subject placing the forearm area that was exposed to the UV burn on the oscillatory device and informing the investigators when the first perception of vibration is felt. A recording of the frequency (1 kilo Hertz to 1 Hertz) will be documented.</description>
        <time_frame>From 5 minutes to 120 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for vibration FREQUENCY detection threshold and the last 5 participants were tested for vibration INTENSITY detection threshold. This outcome relates to the first 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection</title>
          <description>Vibration frequency detection threshold in the burned area after IM Oxytocin or placebo injection will be obtained by the subject placing the forearm area that was exposed to the UV burn on the oscillatory device and informing the investigators when the first perception of vibration is felt. A recording of the frequency (1 kilo Hertz to 1 Hertz) will be documented.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for vibration FREQUENCY detection threshold and the last 5 participants were tested for vibration INTENSITY detection threshold. This outcome relates to the first 5 participants only.</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="14"/>
                    <measurement group_id="O2" value="21" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory analysis without power calculation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.83</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures one factor ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Threshold (the Point Where Pain is First Perceived) to a Punctate Mechanical Stimulus After IM Injection.</title>
        <description>Verbal pain punctate stimulus detection threshold (the point where pain is first perceived) in the burned area after IM Oxytocin or Placebo injection will be obtained by using von Frey filaments (small filaments that are similar to a paint brush bristle). The skin will be touched with the filaments and the participant will state when pain is perceived and the size of the filament will be documented.</description>
        <time_frame>From 5 minutes to 120 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain THRESHOLD to mechanical stimulation and the last 5 participants were tested for degree of pain INTENSITY to a fixed mechanical stimulation. This outcome relates to the first 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Threshold (the Point Where Pain is First Perceived) to a Punctate Mechanical Stimulus After IM Injection.</title>
          <description>Verbal pain punctate stimulus detection threshold (the point where pain is first perceived) in the burned area after IM Oxytocin or Placebo injection will be obtained by using von Frey filaments (small filaments that are similar to a paint brush bristle). The skin will be touched with the filaments and the participant will state when pain is perceived and the size of the filament will be documented.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain THRESHOLD to mechanical stimulation and the last 5 participants were tested for degree of pain INTENSITY to a fixed mechanical stimulation. This outcome relates to the first 5 participants only.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.66"/>
                    <measurement group_id="O2" value="0.29" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory analysis without power calculation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.92</p_value>
            <method>ANOVA</method>
            <method_desc>One factor repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hypersensitivity to Von Frey Filament (225 milliNewton) After IM Injection.</title>
        <description>Hypersensitivity in the burned area after IM Oxytocin or placebo injection will be obtained by using a von Frey filament (small filament that is similar to a paint brush bristle). The skin will be touched with the filament and the participant will state when sensitivity is perceived and the area marked and measured in centimeters squared.</description>
        <time_frame>From 5 minutes to 65 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain THRESHOLD to mechanical stimulation and the last 5 participants were tested for degree of pain INTENSITY to a fixed mechanical stimulation. This outcome relates to the last 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypersensitivity to Von Frey Filament (225 milliNewton) After IM Injection.</title>
          <description>Hypersensitivity in the burned area after IM Oxytocin or placebo injection will be obtained by using a von Frey filament (small filament that is similar to a paint brush bristle). The skin will be touched with the filament and the participant will state when sensitivity is perceived and the area marked and measured in centimeters squared.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain THRESHOLD to mechanical stimulation and the last 5 participants were tested for degree of pain INTENSITY to a fixed mechanical stimulation. This outcome relates to the last 5 participants only.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="8.6"/>
                    <measurement group_id="O2" value="8.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory analysis without power calculation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.79</p_value>
            <method>ANOVA</method>
            <method_desc>One factor repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Vibration Frequency Detection of Fixed Frequency (When Vibration is First Felt) After IM Injection</title>
        <description>Vibration frequency detection of a fixed frequency (256 Hertz) in the burned area after IM Oxytocin or placebo injection will be obtained. The subject will place the wrist area that was exposed to the UV burn on the oscillatory device, the fixed vibratory frequency will begin and will be increased in intensity and the subject will inform the investigators when the first perception of vibration is felt. A recording of the intensity level will be documented in Hertz.</description>
        <time_frame>From 5 minutes to 65 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for vibration FREQUENCY detection threshold and the last 5 participants were tested for vibration INTENSITY detection threshold. This outcome relates to the last 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vibration Frequency Detection of Fixed Frequency (When Vibration is First Felt) After IM Injection</title>
          <description>Vibration frequency detection of a fixed frequency (256 Hertz) in the burned area after IM Oxytocin or placebo injection will be obtained. The subject will place the wrist area that was exposed to the UV burn on the oscillatory device, the fixed vibratory frequency will begin and will be increased in intensity and the subject will inform the investigators when the first perception of vibration is felt. A recording of the intensity level will be documented in Hertz.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for vibration FREQUENCY detection threshold and the last 5 participants were tested for vibration INTENSITY detection threshold. This outcome relates to the last 5 participants only.</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.4"/>
                    <measurement group_id="O2" value="1.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.93</p_value>
            <p_value_desc>Exploratory analysis without power calculation</p_value_desc>
            <method>ANOVA</method>
            <method_desc>One factor repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sustained Heat After IM Injection Non Dominant Arm</title>
        <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature after IM Oxytocin or placebo injection.</description>
        <time_frame>From 21 minutes to 125 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain report to sustained heat applied to the ARM and the last 5 participants were tested for pain report to sustained heat applied to the LEG. This outcome relates to the first 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sustained Heat After IM Injection Non Dominant Arm</title>
          <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature after IM Oxytocin or placebo injection.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain report to sustained heat applied to the ARM and the last 5 participants were tested for pain report to sustained heat applied to the LEG. This outcome relates to the first 5 participants only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.65"/>
                    <measurement group_id="O2" value="-0.70" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.89</p_value>
            <p_value_desc>Exploratory analysis without power calculation</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Two factor repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sustained Heat After IM Injection</title>
        <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 40 degree Celsius temperature applied to the site of the UV burn after IM Oxytocin or placebo injection.</description>
        <time_frame>From 36 minutes to 40 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. Only the last 5 participants were tested for pain report to sustain heat applied at the site of the UV-B burn.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sustained Heat After IM Injection</title>
          <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 40 degree Celsius temperature applied to the site of the UV burn after IM Oxytocin or placebo injection.</description>
          <population>Please note that the protocol was amended after the first 5 participants. Only the last 5 participants were tested for pain report to sustain heat applied at the site of the UV-B burn.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.22"/>
                    <measurement group_id="O2" value="-0.20" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power calculation</non_inferiority_desc>
            <p_value>0.83</p_value>
            <p_value_desc>Exploratory analysis without power calculation</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Two way repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sustained Heat After IM Oxytocin or Placebo Injection (Lower Leg)</title>
        <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature applied to the calf (lower leg) after IM Oxytocin or placebo injection.</description>
        <time_frame>From 21 minutes to 65 minutes</time_frame>
        <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain report to sustained heat applied to the ARM and the last 5 participants were tested for pain report to sustained heat applied to the LEG. This outcome relates to the last 5 participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sustained Heat After IM Oxytocin or Placebo Injection (Lower Leg)</title>
          <description>Verbal pain scores (0 to 10; 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable) to 45 degree Celsius temperature applied to the calf (lower leg) after IM Oxytocin or placebo injection.</description>
          <population>Please note that the protocol was amended after the first 5 participants. The first 5 participants were tested for pain report to sustained heat applied to the ARM and the last 5 participants were tested for pain report to sustained heat applied to the LEG. This outcome relates to the last 5 participants only.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.94"/>
                    <measurement group_id="O2" value="0.10" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Exploratory analysis without power caclulation</non_inferiority_desc>
            <p_value>0.57</p_value>
            <p_value_desc>Exploratory analysis without power caclulation</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Two way repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 Days</time_frame>
      <desc>This is a randomized, blinded, cross over design with treatment with oxytocin one day and placebo on another. Following baseline measures on each of the two study days, participants received an intramuscular injection of oxytocin (Pitocin®) in its indicated dose of 10 IU (17 μg) or an equivalent volume of saline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin</title>
          <description>Oxytocin: 10 IU oxytocin (Pitocin) for intramuscular injection</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline: 1.5 ml preservative free saline for intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Eisenach</name_or_title>
      <organization>Wake Forest Health Sciences</organization>
      <phone>3367164182</phone>
      <email>eisenach@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

